Short answer
Inhibrx Biosciences, Inc. (INBX) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$33M
- +22.8% YoY
- EPS (diluted)
- −$2.15
- +23.2% YoY
Source: XBRL data from the Inhibrx Biosciences, Inc. (INBX) Q1 2026 10-Q on SEC EDGAR. USD.
Inhibrx Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in submitted text
- First Amendment to Loan and Security Agreement dated March 18, 2026, included as a filed exhibit
- No director or officer adopted or terminated Rule 10b5-1 arrangements during quarter ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibrx Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.